Interferon Treatment of Hepatitis C Virus Infection: From Basic Biology to Clinical Application

  • Norihiro Furusyo
  • Masayuki Murata
  • Jun Hayashi


Chronic Hepatitis Sustained Virological Response Acute Hepatitis Sustained Response Interferon Treatment 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alberti, A., Benvegnu, L. (2003) Management of hepatitis C. Journal of Hepatology, 36: S104–S118.CrossRefGoogle Scholar
  2. Alric, L., Fort, M., Izopet, J., Vinel, J.P., Charlet, J.P., Selves, J., Puel, J., Pascal, J.P., Duffaut, M., Abbal, M. (1997) Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. Gastroenterology, 113: 1675–1681.PubMedCrossRefGoogle Scholar
  3. Annicchiarico, B.E., Siciliano, M. (2004) Pegylated interferon-alpha 2b monotherapy for haemodialysis patients with chronic hepatitis C. Alimentary Pharmacology Therapy, 20: 123–124.CrossRefGoogle Scholar
  4. Bennett, W.G., Inoue, Y., Beck, J.R., Wong, J.B., Pauker, S.G., Davis, G.L. (1997) Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Annals of Internal Medicine, 127: 855–865.PubMedGoogle Scholar
  5. Berenguer, M., Prieto, M., Rayon, J.M., Mora, J., Pastor, M., Ortiz, V., Carrasco, D., San Juan, F., Burgueno, M.D., Mir, J., Berenguer, J. (2000) Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology, 32: 852–858.PubMedCrossRefGoogle Scholar
  6. Berenguer, M. (2003) Host and donor risk factors before and after liver transplantation that impact HCV recurrence. Liver Transplantation, 9: S44–S47.PubMedCrossRefGoogle Scholar
  7. Berg, T., Sarrazin, C., Herrmann, E., Hinrichsen, H., Gerlach, T., Zachoval, R., Wiedenmann, B., Hopf, U., Zeuzem, S. (2003) Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology, 37: 600–609.PubMedCrossRefGoogle Scholar
  8. Bloom, R.D., Rao, V., Weng, F., Grossman, R.A., Cohen, D., Mange, K.C. (2002) Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. Journal of the American Society of Nephrology, 13: 1374–1380.PubMedCrossRefGoogle Scholar
  9. Brouwer, J.T., Nevens, F., Kleter, B., Elewaut, A., Adler, M., Brenard, R., Chamuleau, R.A., Michielsen, P.P., Pirotte, J., Hautekeete, M.L., Weber, J., Bourgeois, N., Hansen, B.E., Bronkhorst, C.M., ten Kate, F.J., Heijtink, R.A., Fevery, J., Schalm, S.W. (1998) Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients. Journal of Hepatology, 28: 951–959.PubMedCrossRefGoogle Scholar
  10. Bruchfeld, A., Lindahl, K., Stahle, L., Soderberg, M., Schvarcz, R. (2003) Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrology Dialysis Transplantation, 18: 1573–1580.CrossRefGoogle Scholar
  11. Bruchfeld, A., Wilczek, H., Elinder, C.G. (2004) Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation. Transplantation, 78: 745–750.PubMedCrossRefGoogle Scholar
  12. Bruchfeld, A., Lindahl, K., Reichard, O., Carlsson, T., Schvarcz, R. (2006) Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. Journal of Viral Hepatitis, 13: 316–321.PubMedCrossRefGoogle Scholar
  13. Buti, M., Sanchez-Avila, F., Lurie, Y., Stalgis, C., Valdes, A., Martell, M., Esteban, R. (2002) Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alpha-2b plus ribavirin. Hepatology, 35: 930–936.PubMedCrossRefGoogle Scholar
  14. Castro, F.J., Esteban, J.I., Juarez, A., Sauleda, S., Viladomiu, L., Martell, M., Moreno, F., Allende, H., Esteban, R., Guardia, J. (2002) Early detection of nonresponse to interferon plus ribavirin combination treatment of chronic hepatitis C. Journal of Viral Hepatitis, 9: 202–207.PubMedCrossRefGoogle Scholar
  15. Charlton, M. (2003) Natural history of hepatitis C and outcomes following liver transplantation, Clinical Liver Disease, 7: 585–602.CrossRefGoogle Scholar
  16. Choo, Q.L., Kuo, G., Weiner, A.J., Overby, L.R., Bradley, D.W., Houghton, M. (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science, 244: 359–362.PubMedCrossRefGoogle Scholar
  17. Chung, R.T., Andersen, J., Volberding, P., Robbins, G.K., Liu, T., Sherman, K.E., Peters, M.G., Koziel, M.J., Bhan, A.K., Alston, B., Colquhoun, D., Nevin, T., Harb, G., van der Horst, C., AIDS Clinical Trials Group A5071 Study Team (2004) Peginterferon alpha-2a plus ribavirin versus interferon alpha-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. New England Journal of Medicine, 351: 451–459.PubMedCrossRefGoogle Scholar
  18. Corrao, G., Arico, S. (1998) Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology, 27: 914–919.PubMedCrossRefGoogle Scholar
  19. Cramp, M.E., Rossol, S., Chokshi, S., Carucci, P., Williams, R., Naoumov, N.V. (2000) Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. Gastroenterology, 118: 346–355.PubMedCrossRefGoogle Scholar
  20. Crosse, K., Umeadi, O.G., Anania, F.A., Laurin, J., Papadimitriou, J., Drachenberg, C., Howell, C.D. (2004) Racial differences in liver inflammation and fibrosis related to chronic hepatitis C. Clinical Gastroenterology Hepatology, 2: 463–468.CrossRefGoogle Scholar
  21. Crotty, S., Maag, D., Arnold, J.J., Zhong, W., Lau, J.Y., Hong, Z., Andino, R., Cameron, C.E. (2000) The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Natural Medicine, 6: 1357–1379.Google Scholar
  22. Cruzado, J.M., Carrera, M., Torras, J., Grinyo, J.M. (2001) Hepatitis C virus infection and de novo glomerular lesions in renal allografts. American Journal of Transplants, 1: 171–178.CrossRefGoogle Scholar
  23. Davis, G.L. (2002) Monitoring of viral levels during therapy of hepatitis C. Hepatology, 36: S145–S145.PubMedCrossRefGoogle Scholar
  24. Davis, G.L., Wong, J.B., McHutchison, J.G., Manns, M.P., Harvey, J., Albrecht, J. (2003) Early virologic response to treatment with peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C. Hepatology, 38: 645–652.PubMedCrossRefGoogle Scholar
  25. Di Bisceglie, A.M., Conjeevaram, H.S., Fried, M.W., Sallie, R., Park, Y., Yurdaydin, C., Swain, M., Kleiner, D.E., Mahaney, K., Hoofnagle, J.H. (1995) Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine, 123: 897–903.PubMedGoogle Scholar
  26. Dienstag, J.L. (2002) The role of liver biopsy in chronic hepatitis C. Hepatology, 36: S152–S160.PubMedCrossRefGoogle Scholar
  27. Dienstag, J.L., McHutchison, J.G. (2006) American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology, 130: 225–230.PubMedCrossRefGoogle Scholar
  28. Dixit, N.M., Layden-Almer, J.E., Layden, T.J., Perelson, A.S. (2004) Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature, 432: 922–924.PubMedCrossRefGoogle Scholar
  29. Everson, G.T. (2005) Should we treat patients with chronic hepatitis C on the waiting list? Journal of Hepatology, 42: 456–462.PubMedCrossRefGoogle Scholar
  30. Fabrizi, F., Poordad, F.F., Martin, P. (2002) Hepatitis C infection and the patient with end-stage renal disease. Hepatology, 36: 3–10.PubMedCrossRefGoogle Scholar
  31. Fabrizi, F., Dulai, G., Dixit, V., Bunnapradist, S., Martin, P. (2003) Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Alimentary Pharmacology Therapy, 18: 1071–1081.CrossRefGoogle Scholar
  32. Frese, M., Schwarzle, V., Barth, K., Krieger, N., Lohmann, V., Mihm, S., Haller, O., Bartenschlager, R. (2002) Interferon-gamma inhibits replication of subgenomic and genomic hepatitis C virus RNAs. Hepatology, 35: 694–703.PubMedCrossRefGoogle Scholar
  33. Fried, M.W., Shiffman, M.L., Reddy, K.R., Smith, C., Marinos, G., Goncales, F.L., Jr., Haussinger, D., Diago, M., Carosi, G., Dhumeaux, D., Craxi, A., Lin, A., Hoffman, J., Yu, J. (2002) Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine, 347: 975–982.PubMedCrossRefGoogle Scholar
  34. Furusyo, N., Hayashi, J., Ueno, K., Sawayama, Y., Kawakami, Y., Kishihara, Y., Kashiwagi, S. (1997) Human lymphoblastoid interferon treatment for patients with hepatitis C virus-related cirrhosis. Clinical Therapy, 19: 1352–1367.CrossRefGoogle Scholar
  35. Furusyo, N., Hayashi, J., Kanamoto-Tanaka, Y., Ariyama, I., Etoh, Y., Shigematsu, M., Kashiwagi, S. (2000a). Liver damage in hemodialysis patients with hepatitis C virus viremia: a prospective 10-year study. Digestive Diseases and Sciences, 45: 2221–2228.CrossRefGoogle Scholar
  36. Furusyo, N., Hayashi, J., Ariyama, I., Sawayama, Y., Etoh, Y., Shigematsu, M., Kashiwagi, S. (2000b). Maintenance hemodialysis decreases serum hepatitis C virus (HCV) RNA levels in hemodialysis patients with chronic HCV infection. American Journal of Gastroenterology, 95: 490–496.CrossRefGoogle Scholar
  37. Furusyo, N., Hayashi, J., Kakuda, K., Ariyama, I., Kanamoto-Tanaka, Y., Shimizu, C., Etoh, Y., Shigematsu, M., Kashiwagi, S. (2001) Acute hepatitis C among Japanese hemodialysis patients: a prospective 9-year study. American Journal of Gastroenterology, 96: 1592–1600.PubMedCrossRefGoogle Scholar
  38. Furusyo, N., Hayashi, J., Kashiwagi, K., Nakashima, H., Nabeshima, S., Sawayama, Y., Kinukawa, N., Kashiwagi, S. (2002) Hepatitis C virus (HCV) RNA level determined by second-generation branched-DNA probe assay as predictor of response to interferon treatment in patients with chronic HCV viremia. Digestive Diseases and Sciences, 47: 535–542.PubMedCrossRefGoogle Scholar
  39. Furusyo, N., Kubo, N., Nakashima, H., Kashiwagi, K., Etoh, Y., Hayashi, J. (2004) Confirmation of nosocomial hepatitis C virus infection in a hemodialysis unit. Infection Control in Hospital Epidemiology, 25: 584–590.CrossRefGoogle Scholar
  40. Furusyo, N., Kubo, N., Toyoda, K., Takeoka, H., Nabeshima, S., Murata, M., Nakamuta, M., Hayashi, J. (2005) Helper T cell cytokine response to ribavirin priming before combined treatment with interferon alpha and ribavirin for patients with chronic hepatitis C. Antiviral Research, 67: 46–54.PubMedCrossRefGoogle Scholar
  41. Furusyo, N., Katoh, M., Tanabe, Y., Kajiwara, E., Maruyama, T., Shimono, J., Sakai, H., Nakamuta, M., Nomura, H., Masumoto, A., Shimoda, S., Takahashi, K., Azuma, K., Hayashi, J. (2006) Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: a project of the Kyushu University Liver Disease Study Group. World Journal of Gastroenterology, 12: 784–790.PubMedGoogle Scholar
  42. Gane, E. (2002) Treatment of recurrent hepatitis C. Liver Transplantation, 8: S28–S37.PubMedCrossRefGoogle Scholar
  43. Ghany, M.G., Kleiner, D.E., Alter, H., Doo, E., Khokar, F., Promrat, K., Herion, D., Park, Y., Liang, T.J., Hoofnagle, J.H. (2003) Progression of fibrosis in chronic hepatitis C. Gastroenterology, 124: 97–104.PubMedCrossRefGoogle Scholar
  44. Hadziyannis, S.J., Sette, H., Jr., Morgan, T.R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H., Jr., Bernstein, D., Rizzetto, M., Zeuzem, S., Pockros, P.J., Lin, A., Ackrill, A.M., PEGASYS International Study Group (2004) Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Annals of Internal Medicine, 140: 346–355.PubMedGoogle Scholar
  45. Hagiwara, H., Hayashi, N., Mita, E., Ueda, K., Takehara, T., Kasahara, A., Fusamoto, H., Kamada, T. (1992) Detection of hepatitis C virus RNA in serum of patients with chronic hepatitis C treated with interferon-alpha. Hepatology, 15: 37–41.PubMedCrossRefGoogle Scholar
  46. Hayashi, J., Hirata, M., Nakashima, K., Noguchi, A., Kashiwagi, S., Matsui, M., Ishibashi, H., Maeda, Y. (1991a). Hepatitis C virus is a more likely cause of chronic liver disease in the Japanese population than hepatitis B virus. Fukuoka Igaku Zasshi, 82: 648–654.Google Scholar
  47. Hayashi, J., Nakashima, K., Kajiyama, W., Noguchi, A., Morofuji, M., Maeda, Y., Kashiwagi, S. (1991b). Prevalence of antibody to hepatitis C virus in hemodialysis patients. American Journal of Epidemiology, 134: 651–657.Google Scholar
  48. Hayashi, J., Ohmiya, M., Kishihara, Y., Tani, Y., Kinukawa, N., Ikematsu, H., Kashiwagi, S. (1994a). A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. American Journal of Gastroenterology, 89: 2151–2156.Google Scholar
  49. Hayashi, J., Nakashima, K., Yoshimura, E., Kishihara, Y., Ohmiya, M., Hirata, M., Kashiwagi, S. (1994b). Prevalence and role of hepatitis C viraemia in haemodialysis patients in Japan. Journal of Infection, 28: 271–277.CrossRefGoogle Scholar
  50. Hayashi, J., Kishihara, Y., Yamaji, K., Furusyo, N., Yamamoto, T., Pae, Y., Etoh, Y., Ikematsu, H., Kashiwagi, S. (1997a). Hepatitis C viral quasispecies and liver damage in patients with chronic hepatitis C virus infection. Hepatology, 25: 697–701.CrossRefGoogle Scholar
  51. Hayashi, J., Kishihara, Y., Yoshimura, E., Furusyo, N., Yamaji, K., Kawakami, Y., Murakami, H., Kashiwagi, S. (1997b). Correlation between human T cell lymphotropic virus type-1 and Strongyloides stercoralis infections and serum immunoglobulin E responses in residents of Okinawa, Japan. American Journal of Tropical Medicine Hygiene, 56: 71–75.Google Scholar
  52. Hayashi, J., Kishihara, Y., Ueno, K., Yamaji, K., Kawakami, Y., Furusyo, N., Sawayama, Y., Kashiwagi, S. (1998a). Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection. Archives of Internal Medicine, 158: 177–181.CrossRefGoogle Scholar
  53. Hayashi, J., Kawakami, Y., Nabeshima, A., Kishihara, Y., Furusyo, N., Sawayama, Y., Kinukawa, N., Kashiwagi, S. (1998b). Comparison of HCV RNA levels by branched DNA probe assay and by competitive polymerase chain reaction to predict effectiveness of interferon treatment for patients with chronic hepatitis C virus. Digestive Diseases and Sciences, 43: 384–391.CrossRefGoogle Scholar
  54. Hayashi, J., Furusyo, N., Ariyama, I., Sawayama, Y., Etoh, Y., Kashiwagi, S. (2000) A relationship between the evolution of hepatitis C virus variants, liver damage, and hepatocellular carcinoma in patients with hepatitis C viremia. Journal of Infectious Disease, 181: 1523–1527.CrossRefGoogle Scholar
  55. Heathcote, E.J., Shiffman, M.L., Cooksley, W.G., Dusheiko, G.M., Lee, S.S., Balart, L., Reindollar, R., Reddy, R.K., Wright, T.L., Lin, A., Hoffman, J., De Pamphilis, J. (2000) Peginterferon alpha-2a in patients with chronic hepatitis C and cirrhosis. New England Journal of Medicine, 343: 1673–1680.PubMedCrossRefGoogle Scholar
  56. Hoofnagle, J.H., Mullen, K.D., Jones, D.B., Rustgi, V., Di Bisceglie, A., Peters, M., Waggoner, J.G., Park, Y., Jones, E.A. (1986) Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. New England Journal of Medicine, 315: 1575–1578.PubMedCrossRefGoogle Scholar
  57. Hoofnagle, J.H., Lau, D., Conjeevaram, H., Kleiner, D., Di Bisceglie, A.M. (1996) Prolonged therapy of chronic hepatitis C with ribavirin. Journal of Viral Hepatology, 3: 247–252.Google Scholar
  58. Hourigan, L.F., Macdonald, G.A., Purdie, D., Whitehall, V.H., Shorthouse, C., Clouston, A., Powell, E.E. (1999) Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology, 29: 1215–1219.PubMedCrossRefGoogle Scholar
  59. Hugle, T., Cerny, A. (2003) Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C. Reviews in Medical Virology., 13: 361–371.PubMedCrossRefGoogle Scholar
  60. Jaeckel, E., Cornberg, M., Wedemeyer, H., Santantonio, T., Mayer, J., Zankel, M., Pastore, G., Dietrich, M., Trautwein, C., Manns, M.P., German Acute Hepatitis C Therapy Group (2001) Treatment of acute hepatitis C with interferon alpha-2b. New England Journal of Medicine, 345: 1452–1457.Google Scholar
  61. Kasahara, A., Hayashi, N., Mochizuki, K., Takayanagi, M., Yoshioka, K., Kakumu, S., Iijima, A., Urushihara, A., Kiyosawa, K., Okuda, M., Hino, K., Okita, K. (1998) Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology, 27: 1394–1402.PubMedCrossRefGoogle Scholar
  62. Kashiwagi, S., Kajiyama, W., Hayashi, J., Noguchi, A., Nakashima, K., Nomura, H., Ikematsu, H., Sawada, T., Kida, S., Koide, A. (1990) Antibody to p40tax protein of human T cell leukemia virus 1 and infectivity. Journal of Infectious Diseases, 161: 426–429.PubMedGoogle Scholar
  63. Kashiwagi, K., Furusyo, N., Kubo, N., Nakashima, H., Nomura, H., Kashiwagi, S., Hayashi, J. (2003) A prospective comparison of the effect of interferon-alpha and interferon-beta treatment in patients with chronic hepatitis C on the incidence of hepatocellular carcinoma development. Journal of Infection and Chemotherapy, 9: 333–340.PubMedCrossRefGoogle Scholar
  64. Kawakami, Y., Nabeshima, S., Furusyo, N., Sawayama, Y., Hayashi, J., Kashiwagi, S. (2000) Increased frequency of interferon-gamma-producing peripheral blood CD4+ T cells in chronic hepatitis C virus infection. American Journal of Gastroenterology, 95: 227–232.PubMedGoogle Scholar
  65. Kirchner, H. (1984) Interferons, a group of multiple lymphokines. Springer Seminar in Immunopathology, 7: 347–374.Google Scholar
  66. Kishihara, Y., Furusyo, N., Kashiwagi, K., Mitsutake, A., Kashiwagi, S., Hayashi, J. (2001) Human T lymphotropic virus type 1 infection influences hepatitis C virus clearance. Journal of Infectious Disease, 184: 1114–1119.CrossRefGoogle Scholar
  67. Kottilil, S., Polis, M.A., Kovacs, J.A. (2004) HIV Infection, hepatitis C infection, and HAART: hard clinical choices. The Journal of the American Medical Association, 292: 243–250.CrossRefGoogle Scholar
  68. Kubo, N., Furusyo, N., Nakashima, H., Kashiwagi, K., Hayashi, J. (2005) Strenuous physical labor is important as a cause of elevated alanine aminotransferase levels in Japanese patients with chronic hepatitis C viremia. European Journal of Epidemiology, 20: 251–261.PubMedCrossRefGoogle Scholar
  69. Lafeuillade, A., Hittinger, G., Chadapaud, S. (2001) Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet, 357: 280–281.PubMedCrossRefGoogle Scholar
  70. Laskus, T., Radkowski, M., Wang, L.F., Jang, S.J., Vargas, H., Rakela, J. (1998) Hepatitis C virus quasispecies in patients infected with HIV-1: correlation with extrahepatic viral replication. Virology, 248: 164–171.PubMedCrossRefGoogle Scholar
  71. Lau, D.T., Kleiner, D.E., Ghany, M.G., Park, Y., Schmid, P., Hoofnagle, J.H. (1998) 10-year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology, 28: 1121–1127.PubMedCrossRefGoogle Scholar
  72. Lau, J.Y., Tam, R.C., Liang, T.J., Hong, Z. (2002) Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology, 35: 1002–1009.PubMedCrossRefGoogle Scholar
  73. Layden-Almer, J.E., Ribeiro, R.M., Wiley, T., Perelson, A.S., Layden, T.J. (2003) Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin. Hepatology, 37: 1343–1350.PubMedCrossRefGoogle Scholar
  74. Liang, T.J., Rehermann, B., Seeff, L.B., Hoofnagle, J.H. (2000) Pathogenesis, natural history, treatment, and prevention of hepatitis C. Annals of Internal Medicine, 132: 296–305.PubMedGoogle Scholar
  75. Lindsay, K.L., Trepo, C., Heintges, T., Shiffman, M.L., Gordon, S.C., Hoefs, J.C., Schiff, E.R., Goodman, Z.D., Laughlin, M., Yao, R., Albrecht, J.K., Hepatitis Interventional Therapy Group (2001) A randomized, double-blind trial comparing pegylated interferon alpha-2b to interferon alpha-2b as initial treatment for chronic hepatitis C. Hepatology, 34: 395–403.Google Scholar
  76. Luxon, B.A., Grace, M., Brassard, D., Bordens, R. (2002) Pegylated interferons for the treatment of chronic hepatitis C infection. Clinical Therapy, 24: 1363–1383.CrossRefGoogle Scholar
  77. Mangia, A., Santoro, R., Minerva, N., Ricci, G.L., Carretta, V., Persico, M., Vinelli, F., Scotto, G., Bacca, D., Annese, M., Romano, M., Zechini, F., Sogari, F., Spirito, F., Andriulli, A. (2005) Peginterferon alpha-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. New England Journal of Medicine, 352: 2609–2617.PubMedCrossRefGoogle Scholar
  78. Manns, M.P., McHutchison, J.G., Gordon, S.C., Rustgi, V.K., Shiffman, M., Reindollar, R., Goodman, Z.D., Koury, K., Ling, M., Albrecht, J.K. (2001) Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 358: 958–965.PubMedCrossRefGoogle Scholar
  79. Marcellin, P., Boyer, N., Degott, C., Martinot-Peignoux, M., Duchatelle, V., Giostra, E., Areias, J., Erlinger, S., Benhamou, J.P. (1994) Long-term histologic and viral changes in patients with chronic hepatitis C who responded to alpha interferon. Liver, 14: 302–307.PubMedGoogle Scholar
  80. Marcellin, P., Boyer, N., Gervais, A., Martinot, M., Pouteau, M., Castelnau, C., Kilani, A., Areias, J., Auperin, A., Benhamou, J.P., Degott, C., Erlinger, S. (1997) Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Annals of Internal Medicine, 127: 875–881.PubMedGoogle Scholar
  81. McHutchison, J.G., Gordon, S.C., Schiff, E.R., Shiffman, M.L., Lee, W.M., Rustgi, V.K., Goodman, Z.D., Ling, M.H., Cort, S., Albrecht, J.K. (1998) Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. New England Journal of Medicine, 339: 1485–1492.PubMedCrossRefGoogle Scholar
  82. Mohsen, A.H., Easterbrook, P.J., Taylor, C., Portmann, B., Kulasegaram, R., Murad, S., Wiselka, M., Norris, S. (2003) Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut, 52: 1035–1040.PubMedCrossRefGoogle Scholar
  83. Monga, H.K., Rodriguez-Barradas, M.C., Breaux, K., Khattak, K., Troisi, C.L., Velez, M., Yoffe, B. (2001) Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clinical Infectious Disease, 33: 240–247.CrossRefGoogle Scholar
  84. Muir, A.J., Bornstein, J.D., Killenberg, P.G., Atlantic Coast Hepatitis Treatment Group (2004) Peginterferon alpha-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. New England Journal of Medicine, 350: 2265–2271.Google Scholar
  85. Murata, M., Nabeshima, S., Maeda, N., Nakashima, H., Kashiwagi, S., Hayashi, J. (2002) Increased frequency of IFN-gamma-producing peripheral CD8+ T cells with memory-phenotype in patients with chronic hepatitis C. Journal of Medical Virology, 67: 162–170.PubMedCrossRefGoogle Scholar
  86. Murata, M., Nabeshima, S., Kikuchi, K., Yamaji, K., Furusyo, N., Hayashi, J. (2006) A comparison of the antitumor effects of interferon-alpha and beta on human hepatocellular carcinoma cell lines. Cytokine, 33: 121–128.PubMedCrossRefGoogle Scholar
  87. National Institutes of Health Consensus Development Conference statement (2002) Management of Hepatitis C: 2002-June 10–12, 2002. Hepatology, 36: S3–S20.Google Scholar
  88. Neumann, A.U., Lam, N.P., Dahari, H., Gretch, D.R., Wiley, T.E., Layden, T.J., Perelson, A.S. (1998) Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science, 282: 103–107.PubMedCrossRefGoogle Scholar
  89. Niederau, C., Lange, S., Heintges, T., Erhardt, A., Buschkamp, M., Hurter, D., Nawrocki, M., Kruska, L., Hensel, F., Petry, W., Haussinger, D. (1998) Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology, 28: 1687–1695.PubMedCrossRefGoogle Scholar
  90. Nishiguchi, S., Kuroki, T., Nakatani, S., Morimoto, H., Takeda, T., Nakajima, S., Shiomi, S., Seki, S., Kobayashi, K., Otani, S. (1995) Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet, 346: 1051–1055.PubMedCrossRefGoogle Scholar
  91. Nomura, H., Tanimoto, H., Kajiwara, E., Shimono, J., Maruyama, T., Yamashita, N., Nagano, M., Higashi, M., Mukai, T., Matsui, Y., Hayashi, J., Kashiwagi, S., Ishibashi, H. (2004a). Factors contributing to ribavirin-induced anemia. Journal of Gastroenterology and Hepatology, 19: 1312–1317.CrossRefGoogle Scholar
  92. Nomura, H., Sou, S., Tanimoto, H., Nagahama, T., Kimura, Y., Hayashi, J., Ishibashi, H., Kashiwagi, S. (2004b). Short-term interferon-alpha therapy for acute hepatitis C: a randomized controlled trial. Hepatology, 39: 1213–1219.CrossRefGoogle Scholar
  93. Okanoue, T., Itoh, Y., Minami, M., Sakamoto, S., Yasui, K., Sakamoto, M., Nishioji, K., Murakami, Y., Kashima K. (1999) Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. Journal of Hepatology, 30: 653–659.PubMedCrossRefGoogle Scholar
  94. Pereira, B.J., Natov, S.N., Bouthot, B.A., Murthy, B.V., Ruthazer, R., Schmid, C.H., Levey, A.S. (1998) Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney International, 53: 1374–1381.PubMedCrossRefGoogle Scholar
  95. Perez-Olmeda, M., Nunez, M., Romero, M., Gonzalez, J., Castro, A., Arribas, J.R., Pedreira, J., Barreiro, P., Garcia-Samaniego, J., Martin-Carbonero, L., Jimenez-Nacher, I., Soriano, V. (2003) Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS, 17: 1023–1028.PubMedCrossRefGoogle Scholar
  96. Poynard, T., Bedossa, P., Chevallier, M., Mathurin, P., Lemonnier, C., Trepo, C., Couzigou, P., Payen, J.L., Sajus, M., Costa, J.M. (1995) A comparison of three interferon alpha-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. New England Journal of Medicine, 332: 1457–1462.PubMedCrossRefGoogle Scholar
  97. Poynard, T., Leroy, V., Cohard, M., Thevenot, T., Mathurin, P., Opolon, P., Zarski, J.P. (1996) Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology, 24: 778–789.PubMedCrossRefGoogle Scholar
  98. Poynard, T., Bedossa, P., Opolon, P. (1997) Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet, 349: 825–832.PubMedCrossRefGoogle Scholar
  99. Poynard, T., Marcellin, P., Lee, S.S., Niederau, C., Minuk, G.S., Ideo, G., Bain, V., Heathcote, J., Zeuzem, S., Trepo, C., Albrecht, J. (1998) Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet, 352: 1426–1432.PubMedCrossRefGoogle Scholar
  100. Reddy, K.R., Wright, T.L., Pockros, P.J., Shiffman, M., Everson, G., Reindollar, R., Fried, M.W., Purdum, P.P. 3rd., Jensen, D., Smith, C., Lee, W.M., Boyer, T.D., Lin, A., Pedder, S., DePamphilis, J. (2001) Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology, 33: 433–438.PubMedCrossRefGoogle Scholar
  101. Robertson, B., Myers, G., Howard, C., Brettin, T., Bukh, J., Gaschen, B., Gojobori, T., Maertens, G., Mizokami, M., Nainan, O., Netesov, S., Nishioka, K., Shini, T., Simmonds, P., Smith, D., Stuyver, L., Weiner, A. (1998) Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: Proposals for standardization. International Committee on Virus Taxonomy. Archives of Virology, 143: 2493–2503.PubMedCrossRefGoogle Scholar
  102. Rodriguez-Luna, H., Khatib, A., Sharma, P., De Petris, G., Williams, J.W., Ortiz, J., Hansen, K., Mulligan, D., Moss, A., Douglas, D.D., Balan, V.. Rakela, J., Vargas, H.E. (2004) Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha2b and ribavirin: an open-label series. Transplantation, 77: 190–194.PubMedCrossRefGoogle Scholar
  103. Russo, M.W., Goldsweig, C.D., Jacobson, I.M., Brown, R.S., Jr. (2003) Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. American Journal of Gastroenterology, 98: 1610–1615.PubMedCrossRefGoogle Scholar
  104. Sanchez-Tapias, J.M., Diago, M., Escartin, P., Enriquez, J., Romero-Gomez, M., Barcena, R., Crespo, J., Andrade, R., Martinez-Bauer, E., Perez, R., Testillano, M., Planas, R., Sola, R., Garcia-Bengoechea, M., Garcia-Samaniego, J., Munoz-Sanchez, M., Moreno-Otero, R., TeraViC-4 Study Group (2006) Peginterferon-alpha2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology, 131: 451–460.PubMedCrossRefGoogle Scholar
  105. Scott, L.J., Perry, C.M. (2002) Interferon-alpha-2b plus ribavirin: A review of its use in the management of chronic hepatitis C. Drugs, 62: 507–556.PubMedCrossRefGoogle Scholar
  106. Sheeff, L.B., Hoofnagle, J.H. (2002) National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology, 36: S1–S2.Google Scholar
  107. Shiffman, M.L., Di Bisceglie, A.M., Lindsay, K.L., Morishima, C., Wright, E.C., Everson, G.T., Lok, A.S., Morgan, T.R., Bonkovsky, H.L., Lee, W.M., Dienstag, J.L., Ghany, M.G., Goodman, Z.D., Everhart, J.E., Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial Group (2004) Peginterferon alpha-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology, 126: 1015–1023.Google Scholar
  108. Shindo, M., Di Bisceglie, A.M., Cheung, L., Shih, J.W., Cristiano, K., Feinstone, S.M., Hoofnagle, J.H. (1991) Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Annals of Internal Medicine, 115: 700–704.PubMedGoogle Scholar
  109. Soza, A., Heller, T., Ghany, M., Lutchman, G., Jake Liang, T., Germain, J., Hsu, H.H., Park, Y., Hoofnagle, J.H. (2005) Pilot study of interferon gamma for chronic hepatitis C. Journal of Hepatology, 43: 67–71.PubMedCrossRefGoogle Scholar
  110. Sporea, I., Sirli, R., Golea, O., Totolici, C., Danila, M., Popescu, A. (2004) Peg-interferon alpha 2a (40kDa) in patients on chronic haemodialysis with chronic C hepatitis. Preliminary results. Roman Journal of Gastroenterology, 13: 99–102.Google Scholar
  111. Strader, D.B., Wright, T., Thomas, D.L., Seeff, L.B., American Association for the Study of Liver Diseases (2004) Diagnosis, management, and treatment of hepatitis C. Hepatology, 39: 1147–1171.Google Scholar
  112. Thomas, D.L., Astemborski, J., Rai, R.M., Anania, F.A., Schaeffer, M., Galai, N., Nolt, K., Nelson, K.E., Strathdee, S.A., Johnson, L., Laeyendecker, O., Boitnott, J., Wilson, L.E., Vlahov, D. (2000) The natural history of hepatitis C virus infection: host, viral, and environmental factors, The Journal of the American Medical Association, 284: 450–456.CrossRefGoogle Scholar
  113. Tilg, H. (1997) New insights into the mechanisms of interferon alpha: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology, 112: 1017–1021.PubMedCrossRefGoogle Scholar
  114. Torriani, F.J., Rodriguez-Torres, M., Rockstroh, J.K., Lissen, E., Gonzalez-Garcia, J., Lazzarin, A., Carosi, G., Sasadeusz, J., Katlama, C., Montaner, J., Sette, H., Jr., Passe, S., De Pamphilis, J., Duff, F., Schrenk, U.M., Dieterich, D.T., APRICOT Study Group (2004) Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. New England Journal of Medicine, 351: 438–450.PubMedCrossRefGoogle Scholar
  115. Yamaji, K., Hayashi, J., Kawakami, Y., Furusyo, N., Sawayama, Y., Kishihara, Y., Etoh, Y., Kashiwagi, S. (1998) Hepatitis C viral RNA status at two weeks of therapy predicts the eventual response. Journal of Clinical Gastroenterology, 26: 193–199.PubMedCrossRefGoogle Scholar
  116. Yano, M., Kumada, H., Kage, M., Ikeda, K., Shimamatsu, K., Inoue, O., Hashimoto, E., Lefkowitch, J.H., Ludwig, J., Okuda, K. (1996) The long-term pathological evolution of chronic hepatitis C. Hepatology, 23: 1334–1340.PubMedCrossRefGoogle Scholar
  117. Yoshida, H., Shiratori, Y., Moriyama, M., Arakawa, Y., Ide, T., Sata, M., Inoue, O., Yano, M., Tanaka, M., Fujiyama, S., Nishiguchi, S., Kuroki, T., Imazeki, F., Yokosuka, O., Kinoyama, S, Yamada, G., Omata, M. (1999) Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of hepatocarcinogenesis by interferon therapy. Annals of Internal Medicine, 131: 174–181.PubMedGoogle Scholar
  118. Zeuzem, S., Schmidt, J.M., Lee, J.H., von Wagner, M., Teuber, G., Roth, W.K. (1998) Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alpha on viral turnover. Hepatology, 28: 245–252.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Norihiro Furusyo
    • 1
  • Masayuki Murata
  • Jun Hayashi
  1. 1.Department of General MedicineKyushu University HospitalHigashi-KuJapan

Personalised recommendations